Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Plus Chemotherapy in First-Line Advanced Urothelial Carcinoma
NCT03967977Phase 3Active, not recruiting
- Sponsor
- BeiGene
- Start
- May 2019
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of tislelizumab in urothelial carcinoma (UC), sponsored by BeiGene. Started May 2019; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03967977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03967977.